Is ‘theragnomics’ the future in molecular imaging?

Combining theranostics and radiomics – a new concept termed “theragnomics” – could be the key to realizing the full potential of molecular imaging of cancer patients, according to a presentation delivered February 28 at ECR 2024. Desiree Deandreis, MD, of Gustave Roussy Cancer Treatment Center in Villejuif, France, described the concept and noted that its goal is to harness imaging power to improve patient selection for treatment, identify how patients respond to therapy, integrate new prognostic biomarkers, and ultimately improve the efficacy of new treatments. “My question is all the ways we can shift from a simple theranostic model to a complex model,” she told session attendees. Theranostics is itself a portmanteau of "therapy" and diagnostics" and refers to the dual approach of using the same molecular ligands to both image and treat cancer. It is a relatively simple concept that can be summed up by the expression “see what you treat and treat what you see,” Deandreis explained. Promising examples of the approach include the use of prostate-specific membrane antigen (PSMA) PET imaging and drugs such as Pluvicto (lutetium-177 [Lu-177] prostate-specific membrane antigen [PSMA]-617), a radioligand therapy approved in the U.S. in 2022.Desiree Deandreis, MD, discussed the development of a more complex theranostics model that integrates radiomics at ECR 20204 in Vienna. Combining this approach with radiomics – the extraction of data from medical imaging ...
Source: AuntMinnie.com Headlines - Category: Radiology Authors: Tags: Molecular Imaging Source Type: news